Luye Pharma Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Luye Pharma Group wird ein jährliches Gewinn- und Umsatzwachstum von 16.9% bzw. 10.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.7% betragen.

Wichtige Informationen

16.9%

Wachstumsrate der Gewinne

17.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	10.8%
Wachstumsrate der Einnahmen	10.2%
Zukünftige Eigenkapitalrendite	7.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Sep 25

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Aug 29

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20

Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Apr 06

Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Mar 17

Gewinn- und Umsatzwachstumsprognosen

SEHK:2186 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8,048	1,159	N/A	N/A	3
12/31/2025	7,113	941	N/A	N/A	3
12/31/2024	6,396	808	N/A	N/A	3
6/30/2024	6,314	770	-654	511	N/A
3/31/2024	6,228	652	-112	1,053	N/A
12/31/2023	6,143	533	430	1,595	N/A
9/30/2023	6,089	495	503	1,667	N/A
6/30/2023	6,035	458	576	1,739	N/A
3/31/2023	6,008	531	533	1,696	N/A
12/31/2022	5,982	605	490	1,654	N/A
9/30/2022	5,541	190	-407	946	N/A
6/30/2022	5,099	-224	-1,304	238	N/A
3/31/2022	5,150	-179	-1,332	210	N/A
12/31/2021	5,200	-134	-1,359	182	N/A
9/30/2021	5,365	210	-854	629	N/A
6/30/2021	5,529	554	-349	1,075	N/A
3/31/2021	5,534	630	-370	1,054	N/A
12/31/2020	5,540	707	-391	1,033	N/A
9/30/2020	5,864	955	-1,081	1,151	N/A
6/30/2020	6,189	1,204	-1,772	1,268	N/A
3/31/2020	6,273	1,300	-1,694	1,345	N/A
12/31/2019	6,358	1,396	-1,617	1,423	N/A
9/30/2019	6,229	1,434	-1,385	1,377	N/A
6/30/2019	6,101	1,472	-1,153	1,332	N/A
3/31/2019	5,637	1,388	-1,296	1,189	N/A
12/31/2018	5,173	1,303	-1,439	1,046	N/A
9/30/2018	4,671	1,231	-506	1,046	N/A
6/30/2018	4,168	1,159	427	1,046	N/A
3/31/2018	3,991	1,070	N/A	1,005	N/A
12/31/2017	3,815	981	N/A	964	N/A
9/30/2017	3,547	917	N/A	888	N/A
6/30/2017	3,280	852	N/A	812	N/A
3/31/2017	3,099	872	N/A	702	N/A
12/31/2016	2,918	892	N/A	592	N/A
9/30/2016	2,784	843	N/A	N/A	N/A
6/30/2016	2,649	794	N/A	390	N/A
3/31/2016	2,606	774	N/A	392	N/A
12/31/2015	2,563	755	N/A	395	N/A
9/30/2015	2,481	732	N/A	N/A	N/A
6/30/2015	2,400	710	N/A	423	N/A
3/31/2015	2,472	658	N/A	459	N/A
12/31/2014	2,544	606	N/A	495	N/A
9/30/2014	2,705	534	N/A	438	N/A
6/30/2014	2,866	462	N/A	382	N/A
3/31/2014	2,690	386	N/A	410	N/A
12/31/2013	2,515	310	N/A	439	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 2186Das prognostizierte Gewinnwachstum (16.9% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: 2186Die Erträge des Unternehmens (16.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (11.6% pro Jahr).

Hohe Wachstumserträge: 2186Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 2186Die Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.8% pro Jahr).

Hohe Wachstumseinnahmen: 2186Die Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 2186Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.7%).

Luye Pharma Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 24%, revenue downgraded

Consensus EPS estimates fall by 11%

Consensus revenue estimates fall to CN¥6.20b

Recent updates

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Consensus EPS estimates increase by 24%, revenue downgraded

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Now 20% overvalued

Now 23% overvalued

Full year 2023 earnings: EPS misses analyst expectations

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 20% undervalued after recent price drop

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Investor sentiment deteriorates as stock falls 17%

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan

Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China

Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting

Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection

Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States

Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)